Scholarlink

Objective <p>The main objective of the study was to compare neonatal outcomes: the incidence of NOWS, length of hospital stay (LOS), admission to neonatal intensive care (NICU), birth weight, treatment with morphine, and head circumference between newborns of mothers who had tapering of buprenorphine (T group) during pregnancy to non-tapering of buprenorphine (NT group).</p> Study design <p>It was a prospective, pilot, case-control trial of pregnant women done in North-East Tennessee in pregnancy with opioid use disorder (OUD) in the tapered (T) group as a part of clinical care while the NT group did not taper medication.</p> Results <p>Significant differences were observed among neonatal outcomes; average birth weight and head circumference (<i>p</i> &lt; 0.05) and admission to NICU (<i>p</i> &lt; 0.05) between the two groups by <i>t</i>-test, and in maternal buprenorphine doses, 1.47 versus 7.6 (<i>p</i> &lt; 0.0001).</p> Conclusion <p>Comprehensive outpatient buprenorphine tapering can be done in OUD pregnancy with improved neonatal outcomes after careful discussion with providers of the risks and benefits.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outpatient tapering of buprenorphine in opioid use disorder pregnancies may improve neonatal outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月10日

查看全文
  • Darshan Shah,
  • Rakesh Adelli,
  • Alyson Chroust,
  • Nicole Lewis,
  • Martin Olsen

摘要

Objective

The main objective of the study was to compare neonatal outcomes: the incidence of NOWS, length of hospital stay (LOS), admission to neonatal intensive care (NICU), birth weight, treatment with morphine, and head circumference between newborns of mothers who had tapering of buprenorphine (T group) during pregnancy to non-tapering of buprenorphine (NT group).

Study design

It was a prospective, pilot, case-control trial of pregnant women done in North-East Tennessee in pregnancy with opioid use disorder (OUD) in the tapered (T) group as a part of clinical care while the NT group did not taper medication.

Results

Significant differences were observed among neonatal outcomes; average birth weight and head circumference (p < 0.05) and admission to NICU (p < 0.05) between the two groups by t-test, and in maternal buprenorphine doses, 1.47 versus 7.6 (p < 0.0001).

Conclusion

Comprehensive outpatient buprenorphine tapering can be done in OUD pregnancy with improved neonatal outcomes after careful discussion with providers of the risks and benefits.